Elaprase
Elaprase ingredients
| Active ingredient | Strength |
|---|---|
| Idursulfase | 6 mg/3mL |
What Elaprase is used for
The FDA lists the approved uses on the official label (below). In the EU, idursulfase is approved as Elaprase for:
Elaprase is indicated for the long-term treatment of patients with Hunter syndrome (mucopolysaccharidosis II, MPS II). Heterozygous females were not studied in the clinical trials.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Elaprase
- Generic name
- Idursulfase
- Made by
- Takeda Pharmaceuticals America, Inc.
- Forms
- Solution, Concentrate
- Given
- Intravenous
- Drug class
- Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme
- FDA approval
- Biologic licence (BLA) BLA125151
- On the US market since
- 2006
Official information
- Elaprase prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Idursulfase)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Elaprase?
Elaprase (Idursulfase) is a specialist medicine made by Takeda Pharmaceuticals America, Inc., approved by the US FDA.
What are the ingredients of Elaprase?
Elaprase contains Idursulfase (6 mg/3mL).
Is Elaprase approved in Europe?
The same active substance is approved in the EU as Elaprase.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA